Navigation Links
BridgePoint Medical Closes $9.1 Million Series C Financing
Date:3/10/2011

MINNEAPOLIS, March 10, 2011 /PRNewswire/ -- BridgePoint Medical, Inc., a private company developing innovative and proprietary technology in the field of interventional cardiology for crossing coronary and peripheral chronic total occlusions (CTO), announced today that it has completed its third round of financing earlier this year, totaling $9.1 million.  The round was lead by a new strategic investor and joined by existing investors New Enterprise Associates, Polaris Venture Partners, Foundation Medical Partners and Michael Berman. 

Interventional cardiologists are currently unable to broadly treat patients with chronic total occlusions which comprise approximately one third of all patients with coronary artery disease and approximately one half of patients with peripheral artery disease. For these patients, the common alternative is bypass surgery or palliative care. In order to treat a CTO patient with minimally invasive therapy, a physician must first successfully cross the blockage and place a guidewire beyond the occlusion. BridgePoint Medical's CrossBoss™ Catheter and Stingray™ System are uniquely designed to facilitate guidewire placement and subsequent dilatation balloon or Drug Eluting Stent (DES) placement in this challenging anatomy.

"The inability to successfully deliver therapeutic tools severely limits patient options for CTO treatment today.  We believe that BridgePoint Medical has the technology and the team to address this challenge and the potential to reduce the need for highly invasive and expensive bypass surgery," said Andrew Firlik, General Partner, Foundation Medical Partners.

In September, 2010 the company completed the U.S. Facilitated Antegrade Steering Technique in Chronic Total Occlusions (FAST-CTOs) Study.  The study evaluated the ability of the CrossBoss™ Catheter and Stingray™ System to successfully and safely facilitate placement of a guidewire beyond a CTO in the vessel true lumen in cases that were otherwise refractory to treatment with a conventional guidewire. One hundred forty-seven patients were enrolled at 20 sites.  The company has filed a 510(k) with the FDA requesting market clearance for the indication of coronary CTO treatments in the U.S.  

The Series C financing will be used to enable marketing and sales efforts for BridgePoint's CrossBoss™ Catheter and Stingray™ System in the United States, Europe and Japan through the use of distributors and direct sales.  Additionally, BridgePoint Medical will be initiating a U.S. IDE study of the technologies in peripheral artery disease in the first half of 2011.

"The addition of a new investor combined with the continuing commitment of our present investors is a testament to the significant progress we have made in the development and investigation of our CrossBoss™ Catheter and Stingray™ System. This funding will enable us to accelerate growth through initiation of commercialization activities globally," stated Michael Berman of Berman Medical and Chairman of the BridgePoint Board of directors.

About BridgePoint Medical

BridgePoint Medical, Inc. is a privately held company established in 2006 to design, develop and commercialize new technologies and techniques to treat challenging coronary and peripheral artery disease. 


'/>"/>
SOURCE BridgePoint Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries
2. BridgePoint Medical®, Inc. Completes and Submits to FDA in the U.S. FAST-CTOs With the CrossBoss® and Stingray® CTO Recanalization System
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Globus Medical Raises $110 Million in Series E Financing Round
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Boston University Biomedical Engineers Find Chink in Bacterias Armor
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
(Date:4/27/2016)... Inc. (Nasdaq: HOLX ) announced today ... quarter ended March 26, 2016.  GAAP diluted earnings ... non-GAAP diluted EPS of $0.47 increased 14.6%.  Revenue ... basis, and 6.3% on a constant currency basis.  ... highlighted by 14.6% growth in non-GAAP EPS," said ...
(Date:4/27/2016)... York , April 27, 2016 ... report titled, "Skincare Devices Market - Global Industry Analysis, ... According to the report, the global skincare devices market ... is anticipated to expand at a CAGR of 10.1% ... in 2023. Browse the full Skincare Devices Market ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... Further establishing itself as a leader ... new WHIMZEES Variety Value Boxes were selected from over 1,000 entrants as a winner ... , WHIMZEES natural dental chews for dogs are a favorite product among pet-parents worldwide, ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... major organs, such as the kidneys, liver and pancreas. If not properly addressed, ... a board-certified physician in Internal Medicine, Medical Oncology and Palliative Care, warns against ...
(Date:5/2/2016)... ... 2016 , ... According to an American Psychological Association article, the ... before the age of 18. Of those who survive, many still face effects as ... , In her new book, Lyah! Lyah! Pants on Fyah!, she shares stories from ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... and urgent care facilities designed to automate and improve the rapid diagnosis, triage ... it is demonstrating their platform, application, and mobile experience for the first time ...
(Date:5/2/2016)... Charlotte, NC (PRWEB) , ... May 02, 2016 , ... Dr. Jonathan Kulbersh of Carolina ... was listed as number five on the list of “ 5 US Cities with the ... San Francisco, Los Angeles, and Miami. The results were calculated using a survey by ...
Breaking Medicine News(10 mins):